SGN-35T

N/A

Report date: 2025/12/18 16:53:25

Base Information

Drug NameSGN-35T
Drug Alias NameSGN-35TSGN-CD30CPF-08046045
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionHypoxia-inducible factor 1 alpha inhibitorsDNA topoisomerase I inhibitorsTumor necrosis factor receptor superfamily member 8 inhibitors
TargetsHypoxia-inducible factor 1 alphaDNA topoisomerase ITumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsSolid tumoursLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen IncPfizer Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous +[8] 

Other Information

ATC CodeN/A
Related LinksN/A